期刊文献+

Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?

原文传递
导出
摘要 Hepatocellular carcinoma(HCC)is the sixth most commonincident and the fourth most common cause of cancer deathworldwide.It is strongly associated with chronic HepatitisB and C infection and excess alcohol intake(1),makingtreatment of patients with HCC complicated,with the almostuniform presence of concurrent cirrhosis and varying degreesof liver failure,which often fluctuates over time.
出处 《Hepatobiliary Surgery and Nutrition》 SCIE 2019年第5期546-548,共3页 肝胆外科与营养(英文)
关键词 PATIENTS INTAKE DEATH
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部